Clemastine

Overview

Description
A medication used to treat allergy symptoms such as a runny nose and watery eyes.
Description
A medication used to treat allergy symptoms such as a runny nose and watery eyes.
DrugBank ID
DB00283
Type
Small Molecule
US Approved
YES
Other Approved
YES
Clinical Trials
Phase 0
0
Phase 1
6
Phase 2
9
Phase 3
5
Phase 4
0
Therapeutic Categories
  • Histamine Antagonists
Mechanism of Action

Identification

Summary

Clemastine is an antihistamine with sedative and anticholinergic effects used to treat the symptoms of allergic rhinitis.

Brand Names
Wal-hist 12 Hr Relief
Generic Name
Clemastine
DrugBank Accession Number
DB00283
Background

An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 343.89
Monoisotopic: 343.170292166
Chemical Formula
C21H26ClNO
Synonyms
  • (+)-(2R)-2-(2-(((R)-p-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
  • (+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
  • Clemastina
  • Clemastine
  • Clemastinum
External IDs
  • HS-592

Pharmacology

Indication

For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofAllergic rhinitis••••••••••••
Treatment ofAllergic rhinitis•••••••••••••••••
Used in combination to manageAllergic rhinitisCombination Product in combination with: Phenylpropanolamine (DB00397)••••••••••••
Symptomatic treatment ofAngioedema••••••••••••
Symptomatic treatment ofCommon cold••• •••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Clemastine is an antihistamine that also induces anticholinergic and sedative effects. Antihistamines competitively antagonize various physiological effects of histamine including increased capillary permeability and dilatation, the formation of edema, the "flare" and "itch" response, and gastrointestinal and respiratory smooth muscle constriction. Within the vascular tree, H1- receptor antagonists inhibit both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, H1- receptor antagonists can produce CNS stimulation or depression. Most antihistamines exhibit central and/or peripheral anticholinergic activity. Antihistamines act by competitively blocking H1- receptor sites. Antihistamines do not pharmacologically antagonize or chemically inactivate histamine, nor do they prevent the release of histamine.

Mechanism of action

Clemastine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Humans
Absorption

Rapidly absorbed from the gastrointestinal tract.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Antihistamines appear to be metabolized in the liver chiefly via mono- and didemethylation and glucuronide conjugation.

Route of elimination

Urinary excretion is the major mode of elimination.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Oral LD50 in rat and mouse is 3550 mg/kg and 730 mg/kg, respectively. Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. In children, stimulation predominates initially in a syndrome which may include excitement, hallucinations, ataxia, incoordination, muscle twitching, athetosis, hyperthermia, cyanosis convulsions, tremors, and hyperreflexia followed by postictal depression and cardio-respiratory arrest. Convulsions in children may be preceded by mild depression. Dry mouth, fixed dilated pupils, flushing of the face, and fever are common. In adults, CNS depression, ranging from drowsiness to coma, is more common.

Pathways
PathwayCategory
Clemastine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Clemastine is combined with 1,2-Benzodiazepine.
AcebutololThe metabolism of Acebutolol can be decreased when combined with Clemastine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clemastine.
AcetazolamideThe risk or severity of CNS depression can be increased when Clemastine is combined with Acetazolamide.
AcetophenazineThe risk or severity of CNS depression can be increased when Clemastine is combined with Acetophenazine.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Clemastine fumarate19259EGQ3D14976-57-9PMGQWSIVQFOFOQ-YKVZVUFRSA-N
Product Images
International/Other Brands
Agasten (Novartis (Brazil)) / Allerhist-1 / Tavegil (Novartis) / Tavegyl (Novartis) / Tavist (Novartis) / Tavist-1 (Novartis)
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Clemastine FumarateTablet2.68 mg/1OralTeva Pharmaceuticals USA, Inc.1992-04-01Not applicableUS flag
Clemastine FumarateTablet2.68 mg/1OralSandoz S.P.A.1993-10-312016-10-31US flag
Clemastine FumarateTablet2.68 mg/1OralNorthwind Pharmaceuticals, LLC2014-04-282014-06-25US flag
Clemastine FumarateSyrup0.67 mg/5mLOralChartwell Rx, Llc1997-12-17Not applicableUS flag
Clemastine FumarateSyrup0.67 mg/5mLOralLannett Company, Inc.1997-12-17Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Allergy ReliefTablet1.34 mg/1OralCVS Health1996-08-282014-03-21US flag
Clemastine FumarateTablet1.34 mg/1OralCarilion Materials Management1993-10-31Not applicableUS flag
Clemastine FumarateTablet1.34 mg/1OralPhysicians Total Care, Inc.2008-06-27Not applicableUS flag
Clemastine FumarateTablet1.34 mg/1OralSandoz S.P.A.1993-10-312016-10-31US flag
Dayhist AllergyTablet1.34 mg/1OralH E B1995-08-302016-12-16US flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Tavist-D TabletsClemastine fumarate (1 mg) + Phenylpropanolamine hydrochloride (75 mg)Tablet, extended releaseOralNovartis1992-12-312001-04-24Canada flag

Categories

ATC Codes
D04AA14 — ClemastineR06AA54 — Clemastine, combinationsR06AA04 — Clemastine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Benzylethers / Chlorobenzenes / N-alkylpyrrolidines / Aryl chlorides / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Amine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzylether / Chlorobenzene / Dialkyl ether / Diphenylmethane / Ether
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monochlorobenzenes, N-alkylpyrrolidine (CHEBI:3738)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
95QN29S1ID
CAS number
15686-51-8
InChI Key
YNNUSGIPVFPVBX-NHCUHLMSSA-N
InChI
InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
IUPAC Name
(2R)-2-{2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine
SMILES
CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1

References

Synthesis Reference

British Patent 942,152; November 20,1963; assigned to Sandoz Ltd.

General References
  1. Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury. Am Heart J. 1976 May;91(5):607-17. [Article]
  2. Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22. [Article]
Human Metabolome Database
HMDB0014428
KEGG Drug
D03535
KEGG Compound
C06913
PubChem Compound
26987
PubChem Substance
46506492
ChemSpider
25129
BindingDB
94606
RxNav
2578
ChEBI
3738
ChEMBL
CHEMBL1626
ZINC
ZINC000000402830
Therapeutic Targets Database
DAP000322
PharmGKB
PA164776997
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clemastine
MSDS
Download (74.2 KB)

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Not AvailableCompletedNot AvailableSolid Tumors1somestatusstop reasonjust information to hide
Not AvailableCompletedPreventionSafety and Efficacy1somestatusstop reasonjust information to hide
3RecruitingTreatmentChildren / Neurodevelopmental Delay / Williams Syndrome1somestatusstop reasonjust information to hide
3RecruitingTreatmentInternuclear Ophthalmoplegia / Multiple Sclerosis1somestatusstop reasonjust information to hide
3RecruitingTreatmentWilliams Syndrome1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
  • Actavis mid atlantic llc
  • Novex pharma
  • Silarx pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
  • Novartis pharmaceuticals corp
  • Perrigo co
  • Sandoz inc
Packagers
  • Apotex Inc.
  • Boca Pharmacal
  • CVS Pharmacy
  • Dispensing Solutions
  • H.J. Harkins Co. Inc.
  • Kroger Co.
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Novartis AG
  • Novex Pharma
  • Nucare Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Prescript Pharmaceuticals
  • Professional Co.
  • Qualitest
  • Sandoz
  • Silarx Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • United Research Laboratories Inc.
  • Wockhardt Ltd.
Dosage Forms
FormRouteStrength
SyrupOral0.5 mg/5mL
SyrupOral0.5 mg/1mL
SyrupOral0.67 mg/5mL
TabletOral1.34 mg/1
TabletOral2.68 mg/1
SolutionIntramuscular; Intravenous2 mg
GelTopical
SyrupOral
TabletOral
SyrupOral0.5 mg / 5 mL
TabletOral1 mg
Tablet, extended releaseOral
Prices
Unit descriptionCostUnit
Clemastine fumarate powder255.0USD g
Clemastine Fumarate 0.67 mg/5ml Syrup 120ml Bottle22.2USD bottle
Clemastine Fumarate 2.68 mg tablet0.9USD tablet
Clemastine fum 2.68 mg tablet0.86USD tablet
Tavist nd 10 mg tablet0.74USD tablet
Clemastine fum 1.34 mg tablet0.58USD tablet
Tavist-1 1.34 mg tablet0.5USD tablet
Clemastine Fumarate 1.34 mg tablet0.34USD tablet
Dayhist tablet0.31USD tablet
CVS Pharmacy dayhist allergy tablet0.28USD tablet
Dayhist-1 1.34 mg tablet0.25USD tablet
Tavist max-str sinus caplet0.17USD caplet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178 °C (hydrogen fumarate formulation)Not Available
water solubilitySoluble (hydrogen fumarate formulation)Not Available
logP5.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000405 mg/mLALOGPS
logP5.29ALOGPS
logP4.92Chemaxon
logS-5.9ALOGPS
pKa (Strongest Basic)9.55Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area12.47 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity101.65 m3·mol-1Chemaxon
Polarizability39.06 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9942
Blood Brain Barrier+0.9918
Caco-2 permeable+0.6652
P-glycoprotein substrateSubstrate0.6659
P-glycoprotein inhibitor IInhibitor0.808
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.8471
CYP450 2C9 substrateNon-substrate0.819
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7176
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7028
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.7454
CarcinogenicityNon-carcinogens0.8549
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.9450 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5986
hERG inhibition (predictor II)Inhibitor0.8702
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0159-9381000000-2be9b3484b69dbb1ec63
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001l-1915000000-e47fd592bf1617d681f6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-3197000000-7c3770d8fb13d8cd5bb3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-7901000000-d5c2eef4c56ee9ad9cf2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-4931000000-00255db249ba328f7dad
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gc9-3920000000-2f3d62f3e87a8448c45a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-1900000000-f3705f9d64e00d2015a8
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-177.003609
predicted
DarkChem Lite v0.1.0
[M-H]-177.78992
predicted
DeepCCS 1.0 (2019)
[M+H]+177.232009
predicted
DarkChem Lite v0.1.0
[M+H]+180.19118
predicted
DeepCCS 1.0 (2019)
[M+Na]+177.162709
predicted
DarkChem Lite v0.1.0
[M+Na]+187.35234
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter (PubMed:33828102, PubMed:8280179). Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. Also mediates neurotransmission in the central nervous system and thereby regulates circadian rhythms, emotional and locomotor activities as well as cognitive functions (By similarity)
Specific Function
G protein-coupled serotonin receptor activity
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  2. Taniguchi K, Urakami M, Takanaka K: [Effects of antiallergic agents on polymorphonuclear leukocytes. The inhibition of arachidonic acid release and superoxide production]. Nihon Yakurigaku Zasshi. 1987 Aug;90(2):97-103. [Article]
  3. Hallberg T, Dohlsten M, Baldetorp B: Demonstration of histamine receptors on human platelets by flow cytometry. Scand J Haematol. 1984 Feb;32(2):113-8. [Article]
  4. Dorsch W, Hintschich C, Neuhauser J, Weber J: Sequential histamine inhalations cause increased bronchial histamine reactivity in guinea pigs: role of platelets, thromboxanes and prostacyclin. Naunyn Schmiedebergs Arch Pharmacol. 1984 Sep;327(2):148-55. [Article]
  5. Taniguchi K, Masuda Y, Takanaka K: Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils. J Pharmacobiodyn. 1991 Feb;14(2):87-93. [Article]
  6. Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. [Article]
  7. Thomas RH, Browne PD, Kirby JD: The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin. Br J Clin Pharmacol. 1985 Oct;20(4):377-82. [Article]
  8. Thomson NC, Kerr JW: Effect of inhaled H1 and H2 receptor antagonist in normal and asthmatic subjects. Thorax. 1980 Jun;35(6):428-34. [Article]
  9. Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury. Am Heart J. 1976 May;91(5):607-17. [Article]
  10. Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22. [Article]
  11. Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants
Specific Function
anandamide 11,12 epoxidase activity
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Flockhart Table of Drug Interactions [Link]

Drug created at June 13, 2005 13:24 / Updated at November 06, 2024 19:55